A Rollover Study of ARRY-371797 in Patients With LMNA-Related Dilated Cardiomyopathy
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 26 Feb 2018
At a glance
- Drugs ARRY 797 (Primary)
- Indications Cardiomyopathies
- Focus Adverse reactions
- Sponsors Array BioPharma
- 22 Feb 2018 Planned End Date changed from 31 Dec 2018 to 31 Dec 2019.
- 22 Feb 2018 Planned primary completion date changed from 1 Feb 2018 to 1 Feb 2019.
- 22 Feb 2018 Status changed from recruiting to active, no longer recruiting.